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Abstract
Background
Neisseria meningitidis serogroup C (NmC) outbreaks occur infrequently in the African meningitis belt; the most 
recent report of an outbreak of this serogroup was in Burkina Faso, 1979. Médecins sans Frontières (MSF) has 
been responding to outbreaks of meningitis in northwest Nigeria since 2007 with no reported cases of 
serogroup C from 2007-2012. MenAfrivac®, a serogroup A conjugate vaccine, was first used for mass 
vaccination in northwest Nigeria in late 2012. Reactive vaccination using polysaccharide ACYW135 vaccine was 
done by MSF in parts of the region in 2008 and 2009; no other vaccination campaigns are known to have 
occurred in the area during this period. We describe the general characteristics of an outbreak due to a novel 
strain of NmC in Sokoto State, Nigeria, in 2013, and a smaller outbreak in 2014 in the adjacent state, Kebbi.
Methods
Information on cases and deaths was collected using a standard line-list during each week of each meningitis 
outbreak in 2013 and 2014 in northwest Nigeria. Initial serogroup confirmation was by rapid Pastorex 
agglutination tests. Cerebrospinal fluid (CSF) samples from suspected meningitis patients were sent to the WHO 
Reference Laboratory in Oslo, where bacterial isolates, serogrouping, antimicrobial sensitivity testing, genotype 
characterisation and real-time PCR analysis were performed.
Results
In the most highly affected outbreak areas, all of the 856 and 333 clinically suspected meningitis cases were 
treated in 2013 and 2014, respectively. Overall attack (AR) and case fatality (CFR) rates were 673/100,000 
population and 6.8% in 2013, and 165/100,000 and 10.5% in 2014. Both outbreaks affected small geographical 
areas of less than 150km2 and populations of less than 210,000, and occurred in neighbouring regions in two 
adjacent states in the successive years. Initial rapid testing identified NmC as the causative agent. Of the 21 
and 17 CSF samples analysed in Oslo, NmC alone was confirmed in 11 and 10 samples in 2013 and 2014, 
respectively. Samples confirmed as NmC through bacterial culture had sequence type (ST)-10217.
Conclusions
These are the first recorded outbreaks of NmC in the region since 1979, and the sequence (ST)-10217 has not 
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been identified anywhere else in the world. The outbreaks had similar characteristics to previously recorded 
NmC outbreaks. Outbreaks of NmC in 2 consecutive years in northern Nigeria indicate a possible emergence of 
this serogroup. Increased surveillance for multiple serogroups in the region is needed, along with consideration 
of vaccination with conjugate vaccines rather than for NmA alone.
Funding Statement
This study was funded as part of MSF routine operations. The WHO Collaborating Centre for Reference and 
Research on Meningococci, Oslo, funded sample transport media and laboratory serogroup and strain tests.
Background
In the African meningitis belt, and specifically within northern Nigeria, most meningitis outbreaks have been 
caused by N. meningitides serogroup A (NmA), including large (10-100 thousand cases) and widespread 
outbreaks 1,2,3,4. In the past 15 years, there have been an increasing number of large outbreaks caused by N. 
meningitidis serogroups W135 and X 5,6,7,8,9. Outbreaks due to Neisseria meningitidis serogroup C (NmC) have 
also occurred but were smaller and less frequent than NmA outbreaks 4. The last NmC outbreak in this region 
occurred in 1979 in Burkina Faso with 539 cases reported (attack rate (AR) 517/100,000) 10. Outbreaks caused 
by NmC in northern Nigeria are rare, with the last and only recorded outbreak in 1975 with no detailed report 
published 4. Other notable NmC outbreaks occurred in the 1970s in Sao Paulo, Brazil and Ho Chi Minh, Vietnam 
with 2005 (11/100,000 people) and 1015 (>20/100,000 people) cases respectively 4. In the USA, morbidity and 
mortality are higher among young adults in outbreaks caused by NmC compared with other serogroups 11.
Médecins sans Frontières (MSF) has conducted surveillance and response to cerebrospinal meningitis (CSM) 
outbreaks in northwest Nigeria since 2007. Meningitis outbreaks due to NmA in northwest Nigeria in 2008 and 
2009 were recorded with 7601 and 9442 cases, respectively; MSF carried out reactive vaccination using 
polysaccharide ACYW135 vaccine in affected parts of the region in these years. An outbreak due to serogroup 
W135 occurred in 2010 with 2307 cases. From 2007-2012, MSF recorded no outbreak caused by NmC in the 
region. In December 2012, the most recent mass vaccination for meningitis in northwest Nigeria, conducted by 
the National Primary Health Care Development Agency (NPHCDA) of the Ministry of Health (MoH), the World 
Health Organization (WHO) and donor organizations, used MenAfrivac®, a serogroup A conjugate vaccine 12.To 
our knowledge, there has been no mass vaccination specifically targeting NmC alone in this region.
This paper describes the general characteristics of an outbreak due to a novel strain of NmC in Sokoto State, 
Nigeria in early 2013 and a smaller outbreak of the same strain in 2014 in the adjacent state, Kebbi, during 
which time no other serogroups were confirmed in the region.
Methods
Case definition. During this outbreak, the case definition used for CSM for those over 1 year of age was 
sudden onset fever and either neck stiffness or petechial rash. For infants under 1 year of age the case 
definition was sudden onset fever and either bulging fontanelle or petechial rash. Only cases adhering to this 
case definition were treated, had CSF samples taken, and were recorded as a suspected meningitis case.
Data collection. In the four northwestern states of Nigeria, meningitis surveillance is done by the MSF 
Surveillance Nurse through weekly proactive contact with all government disease notification officers. There is 
one notification officer for each Local Government Area in each state, and they are required to contact all health 
posts in their jurisdiction each week. The MSF Surveillance Nurse relays reports of meningitis cases to the MSF 
Emergency Response Unit for follow-up and confirmation using clinical and laboratory criteria. At MSF 
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meningitis case-management sites, information for each case was recorded in a standardized line-list of core 
data. Maps of the outbreak area were created using data from case tracing. Affected population estimates were 
derived by combining the known population, as per the most recent national census, for each ward which had at 
least one case.
The aggregated data used for this paper were collected as part of routine activities which MSF has approval to 
conduct from the MOH. This work met the standards set by the independent MSF Ethics Review Board for 
retrospective analyses of routinely collected programmatic data 13.
Laboratory methods. Cerebral spinal fluid (CSF) samples were collected from all eligible suspected cases at 
the start of the outbreak and tested using the rapid Pastorex® latex agglutination kit. Pastorex test kits were 
kept in controlled, refrigerated storage, between 2 and 8 degrees Celsius. Cold chain procedures were 
maintained while transporting test kits to the field, in Gio’Style boxes with ice-packs. The field team conducted 
quality control tests on the kits with each usage, and returned the kits to refrigerated storage at the end of each 
day. The first 21 and 17 samples in 2013 and 2014, respectively, were inoculated into Trans-isolate media 14
and sent to the WHO Collaborating Centre for Reference and Research on Meningococci, Oslo, for confirmation. 
Bacterial identification was determinedby Gram staining, the oxidase reaction and standard biochemical tests. 
The strains were stored at –80°C in brain heart broth with 15% sterile glycerol or in Greaves solution. N. 
meningitidis strains were serogrouped by slide agglutination with commercial antisera (Remel, GA, USA) 15. 
Antimicrobial susceptibility testing was performed by determination of the minimal inhibitory concentrations 
(MIC) using Etest (AB Biodisk, Solna, Sweden). Isolates were tested for susceptibility to penicillin G, amoxicillin, 
ceftriaxone, ciprofloxacin, chloramphenicol, rifampin, tetracycline and sulphonamides, and classified using the 
breakpoints from the European Committee on Antimicrobial Susceptibility Testing 16.
Genotypic characterization: DNA from each strain was prepared by suspending bacteria in Tris-EDTA buffer 
(10 mM Tris-HCl and 1 mM EDTA), pH 8.0, heating at 95°C for 10 min, and followed by centrifugation at 16,000 
x g for 5 min. The supernatant was used as DNA template for PCR. Multi-locus sequence typing (MLST) was 
performed as described on the MLST website 17. The DNA sequences were compared with those on the MLST 
website for determination of the allele numbers, STs, and clonal complexes of the isolates 18. Variation in the 
porA and fetA genes, coding for the outer membrane proteins PorA and FetA, respectively, was determined by 
DNA sequencing, as described previously 19,20 . New MLST alleles and STs were submitted to the MLST 
database 17 together with the strain serogroup and porA and fetA sequences. PCR analysis of the genes coding 
for the polysaccharide capsule was performed for genogroup determination of non-serogroupable isolates as 
described 21.
PCR analysis of culture negative specimens: DNA from Trans-isolate supernatants was purified using 
QiAmp DNA mini kit (Qiagen) and analysed by real-time PCR for species identification, followed by genogrouping 
if N. meningitidis was identified. Determination of the PorA variant was done by DNA sequencing of the porA 
gene using a nested porA-PCR 22.
Data analysis. Line-lists were entered into an MSF standardized database in Microsoft Excel. Quality checks on 
the data were done weekly. Epidemiological curves and frequency summaries of patient history and symptoms 
were generated in Excel.
Results
Case Numbers and Attack Rates, 2013. During the 20 weeks from February 9th until June 23rd, 2013, a 
total of 856 suspected cases of CSM presented for treatment at MSF or MoH treatment sites in Sokoto State 
(Table 1). The attack rate was 673 cases per 100,000 population in the affected wards of the state (Figure 1). 
Fifty-eight (58) deaths were recorded from treatment centres, giving a case fatality rate (CFR) of 6.8%. During 
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the same period in 2013, some CSM cases were reported and treated by the MoH in Kebbi State, which borders 
Sokoto to the West. Detailed information on the cases from Kebbi State is not available.
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Table 1: All suspected clinical cases and death numbers from the most affected state, with attack rates and 
case fatality rates for each year.
†Population figures are a combination of the population, as per most recent census, of all affected wards which had at 
least one case.
Year State most 
affected
Total 
population 
Affected†
Total 
number of 
cases
Attack Rate 
(per 100,000)
Total 
number of 
deaths
Case 
fatality 
rate (%)
2013 Sokoto 127,097 856 673 58 6.8
2014 Kebbi 201,457 333 165 35 10.5
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Fig. 1: CSM cases presenting for treatment at MSF supported treatment centres in Sokoto state, 
2013, by week of presentation.
Case Numbers and Attack Rates, 2014. In 2014, over the 8 weeks from March 14th until May3rd, 333 cases 
of suspected CSM from Kebbi State presented for treatment at MSF-supported sites. The overall attack rate 
during this outbreak was 165 cases per 100,000 population in the affected wards. The CFR was 10.5% (35 
deaths). One suspected case also presented at a treatment site in Kebbi from the adjacent Sokoto State during 
this time.
Outbreak Demographics and Spread, 2013-2014. Of 856 cases in 2013, age and sex information were 
available for 826 (96%); 404 (49%) were female and 422 (51%) male. The highest proportions of cases were 
found in those aged 5-14 years (n=361; 44%) and 15-29 years (n=235; 29%). In 2014, the sex distribution was 
similar (53% male) to that in 2013, and similarly, those aged 5-29 years constituted about three-quarters of 
cases (57% [5-14 years]; 20% [15-29 years]). The 2013 outbreak was limited to a small geographical area, 
spreading gradually to 44 villages and remaining restricted to a region of 105km2 (Figure 2). The epidemic 
curve for the 2013 outbreak (Figure 1) shows a peak in the 9th epidemiological week, during which time the 
outbreak was mostly restricted to the two index villages with high attack rates. Case numbers in these villages 
then decreased, leading to the low attack rate seen in the 11th week. The increase in weeks 12 and 13 reflects 
presentations from areas outside the index villages. The gradual overall decline in cases after this period seems 
to be due to the subsequent serial rise and fall of cases in other villages. The 2014 outbreak was slightly more 
widespread, affecting 57 villages in a region of approximately 150km2.
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Fig. 2: Affected villages and outbreak spread in Sokoto State in 2013
Each coloured dot represents a village which experienced at least one case in 2013, colour differs based on 
administrative ward. General location of outbreaks in Northwest Nigeria is indicated with a red dot (2013 
outbreak) and a blue dot (2014 outbreak) on the full country map at top left.
Laboratory Results, 2013-2014. In the 2013 outbreak, out of the 856 clinically suspected cases, MSF tested 
77 CSF samples with rapid Pastorex latex agglutination tests; 27 were positive for NmC, and 50 were negative. 
In 2014, out of the 333 clinically suspected cases, MSF tested 27 CSF samples by Pastorex test; 13 were 
positive for NmC and 14 were negative. 21 and 17 Trans-Isolate media inoculated with CSF from suspected 
meningitis patients were sent to the reference laboratory in Oslo in 2013 and 2014, respectively (Table 2). In 
total, 11 (52%) and 10 (59%) samples were confirmed as serogroup C in 2013 and 2014, respectively. Most 
were also confirmed as a new strain with sequencing of ST-10217 PorA type P1.21-15,16 and FetA type F1-7. No 
other serogroups were identified during testing of CSF samples from these outbreaks.
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Table 2: Analyses of the CSF samples sent in Trans-Isolate medium to the Collaborating Centre for Reference 
and Research on Meningococci, Oslo
RT-PCR = Real-Time Polymerase Chain Reaction
†For two samples the serogroup was not confirmed by RT-PCR due to low bacterial load, but the PorA type suggests 
that the same strain was involved.
Year Number of 
CSF 
samples
Number of 
samples 
positive for 
NmC in 
culture
PorA 
type
FetA 
type
Sequence 
type
Number culture-
negative 
samples 
positive for 
NmC in RT-PCR
PorA type of 
RT-PCR 
positive 
samples
2013 21 7 21-
15,16
F1-7 10217 6† All 6 samples: 
21-15,16
2014 17 5 21-
15,16
F1-7 10217 5 4 samples: 21-
15,16
1 sample: 21-
15,16-50
Discussion
These outbreaks were caused by a strain of NmC that has not been seen anywhere else in the world: sequence 
ST-10217 PorA type P1.21-15,16 and FetA type F1-7. As far as we know this is the first meningitis outbreak 
caused by NmC in northern Nigeria since 1975 and in the meningitis belt since 1979 4,10,23 . The seasonal 
pattern and presentation of these outbreaks, in the dry period during and following the Harmattan winds, did 
not differ much from those of other meningitis outbreaks caused by N. meningitidis in sub-Saharan Africa 24,25,
26 The outbreaks were confined to relatively small areas, and did not have the ‘wild fire’ effect more typical of 
meningitis outbreaks caused by NmA 2,4. Age groups with the highest proportion of cases in these outbreaks 
were 5-14 years and 15-29 years, also typical of meningitis, with these ages possibly exposed to more risk 
factors for transmission such as overcrowding and active and passive smoke exposure 11,27,28 .
A relatively high percentage of Pastorex latex agglutination tests, carried out only on patients fitting the clinical 
case definition, had negative results during both the 2013 (64%) and 2014 (48%) outbreaks. This may have 
occurred for a number of reasons, including meningitis symptoms with non-bacterial cause, or self-medication 
with antibiotics or traditional medicines prior to presentation. As there is no other report of Pastorex testing 
being used in a real outbreak situation for NmC, it is uncertain whether these negative test result percentages 
are unusually high.
During the 2013 outbreak, the MSF control strategy consisted of active case finding and health promotion 
activities. Due to heightened security issues and anti-vaccination sentiments in the area, reactive vaccination 
was not done. It is not clear that health promotion activities significantly decreased outbreak spread, though it 
was observed that after initiation of this strategy, cases presented earlier to treatment centres and this could 
have contributed to lower mortality rates in the latter part of the outbreak. In 2014, the Kebbi state MoH, along 
with the WHO, attempted twice to apply for vaccines from the International Coordinating Group; however, 
neither request was granted. The state MoH later received approximately 20,000 doses of ACYW135 
polysaccharide vaccine from the Federal MoH, which was used for reactive vaccination in some affected 
villages; details of vaccination strategy and outcomes were not available to MSF. Similar to the previous year, 
health promotion and active case finding was carried out by MSF teams during the 2014 outbreak. Control 
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strategies employed in 2014 by MSF and the MoH did not clearly impact outbreak spread.
The 2014 NmC outbreak had fewer cases than the 2013 outbreak; however, since the outbreaks occurred in 
different regions and were controlled with different measures we cannot say this signifies a pattern of decrease. 
It is possible that these small, localized outbreaks will precede increasingly widespread occurrence of meningitis 
due to this serogroup (C) in the meningitis belt, as has been noted as a characteristic N. meningitidis outbreak 
pattern4 .
It is possible that the mass vaccination with a conjugate ‘A’ vaccine (MenAfriVac®) in this region a few months 
prior to the 2013 outbreak could have had an influence on the emergence of new strains or less commonly seen 
serogroups, such as NmC. Serogroup replacement following mass meningitis vaccination has been noted in 
west Africa; reports from Niger and Burkina Faso have indicated a significant increase in serogroup W 
prevalence in the years following campaigns with MenAfriVac® around 201029,30. Following a mass 
vaccination with MenAfriVac® in Chad in 2011/2012 it was seen that in one community serogroup A carriage 
decreased from 0.7 to 0.02%, while carriage of “other” serogroups (ie. not A, W, X) increased from 0.4 to 0.7%
31. Because of the possibility of serogroup replacement following vaccination, enhanced surveillance systems in 
the region are a priority32.
Conclusions and Recommendations
NmC outbreaks have emerged in northwest Nigeria in the past 2 years, and there is some evidence of 
serogroup replacement in the meningitis belt following recent mass vaccination with NmA conjugate vaccine. 
Meningitis case surveillance systems, for both serogroup and strain, should continue to be strengthened in this 
region to allow for early identification and proper control (such as vaccination for the appropriate serogroup) of 
outbreaks. If NmC outbreaks become more widespread in northern Nigeria or adjacent regions in the coming 
years, large-scale preventative action may be required; a key measure is to ensure availability of ACYW135 
polysaccharide vaccine for reactive vaccination.
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